Journal of translational medicine · 2025
Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated/MSS metastatic colorectal cancer.
СтатьяКлиническое исследование I фазыПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wei Gui-Xia, Zhou Yu-Wen, Cao Peng, Leng Wei-Bing, Wang Li, Tang Jie, Qiu Meng
Аннотация
INTRODUCTION: Patients with BRAF V600E-mutated/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) are associated with a poor prognosis. Backline treatment has minimal efficacy. Multi-target inhibitors of the RAS-RAF-MEK signaling pathway combined with PD-1 monoclonal antibody may be a promising strategy for BRAF V600E-mutated mCRC.
METHODS: This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg/m2; camrelizumab 200 mg; vemurafenib 960 mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.
RESULTS: This trial enrolled 12 eligible patients. Total 2 patients had DLT: one had grade 3 thrombocytopenia and immune myocarditis, another had grade 3 vaginal bleeding. Adverse events (AEs) of grade 3 or higher occurred in 50% of patients. Grade 3 AEs were mainly drug-related fever (25.0%), drug-related rash (16.7%). Median overall survival (OS) and PFS were 7.19 months and 3.47 months, respectively. The ORR and DCR were 33.3% and 66.7%. One patient achieved CR. three patients achieved PR. An abnormal CD4/CD8 ratio was associated with a higher risk of progression. Different efficacy of VCC regimen may be attributed to the difference in tumor immune environment.
CONCLUSIONS: A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).
METHODS: This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg/m2; camrelizumab 200 mg; vemurafenib 960 mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.
RESULTS: This trial enrolled 12 eligible patients. Total 2 patients had DLT: one had grade 3 thrombocytopenia and immune myocarditis, another had grade 3 vaginal bleeding. Adverse events (AEs) of grade 3 or higher occurred in 50% of patients. Grade 3 AEs were mainly drug-related fever (25.0%), drug-related rash (16.7%). Median overall survival (OS) and PFS were 7.19 months and 3.47 months, respectively. The ORR and DCR were 33.3% and 66.7%. One patient achieved CR. three patients achieved PR. An abnormal CD4/CD8 ratio was associated with a higher risk of progression. Different efficacy of VCC regimen may be attributed to the difference in tumor immune environment.
CONCLUSIONS: A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).